GOSSAMER BIO INC (GOSS) Stock Price, Quote, News and Overview

Company Profile

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company is headquartered in San Diego, California and currently employs 135 full-time employees. The company went IPO on 2019-02-08. The firm is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH). Its product candidate Seralutinib, also known as GB002, is an investigational inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. In contrast to the three classes of marketed vasodilatory therapies for PAH, its seralutinib has the potential to reverse pathological remodeling by addressing mechanisms that underlie PAH. Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways. In addition to PAH, seralutinib holds the potential as a therapeutic option for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Company Info

GOSSAMER BIO INC

3013 Science Park Rd

San Diego CALIFORNIA 92121 US

CEO: Faheem Hasnain

Employees: 135

Company Website: https://www.gossamerbio.com/

Investor Relations: https://ir.gossamerbio.com/

Phone: 18589220718